BIOGEN AND SAMSUNG BIOEPIS TO PRESENT LATEST DATA FOR INFLIXIMAB AND ADALIMUMAB BIOSIMILARS

Biosimilars are products that are demonstrated to be highly similar to reference biological product and have the potential to lower drug costs. In Europe, approximately 170,000 patients have been treated with Biogen and Samsung Bioepis’ anti-TNF biosimilars. Biogen expects the uptake of these products to generate 1.8 billion euros in healthcare cost savings in 2019.

“Patients living with severe autoimmune diseases such as IBD are looking for long-term treatments to safely and effectively control symptoms and improve their quality of life.

Read more